GREENLIGHT RE

Greenlight Capital Re, Ltd.

2022 Investor Day Presentation Thursday, November 17, 2022

GREENLIGHT RE

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Investor Presentation (this "Presentation") is intended solely for the informational purposes of the persons to whom it is presented in connection with the 2022 Investor Day of Greenlight Capital Re, Ltd. (the "Company") to be held on November 17, 2022.

This Presentation includes certain forward-looking statements, estimates, and projections provided by the Company that reflect management's views regarding the anticipated future financial and operating performance of the Company. Forward-looking statements are statements that are not historical, including statements regarding operational and financial plans, terms and performance of the Company and other projections or predictions of the future. Forward-looking statements are typically identified by such words as "project," "believe," "expect," "anticipate," "intend," "estimate," "may," "will," "should," and "could" and similar expressions. Such statements, estimates, and projections reflect numerous assumptions concerning anticipated results, trends and markets that the Company's leadership team believes will impact the Company's development and success based on its current understanding of the industry. The forward-looking statements containing future developments and their potential effects on the Company. As these assumptions may or prove to be correct and there are numerous factors which will affect the Company's actual results (many of which are beyond the Company's control), there can be no assurances that any projected results are estated or will be realized. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise. The Company's actual results may differ materially from those set forth in this Presentation. Accordingly, no representations are made as to the accuracy, reasonableness or completeness of such statements, estimates, or projections.

Certain information contained herein has been derived from publicly available sources prepared by third parties. While such information is believed to be reliable for the purposes used herein, the Company makes no representation or warranty with respect to the accuracy of such information. In this Presentation, the Company relies on and refers to certain information and statistics obtained from third-party sources including reports by market research firms. The Company has not independently verified the accuracy or completeness of any such third-party information. None of the Company, its subsidiaries, their respective affiliates or their respective employees, directors, officers, contractors, advisors, members, successors, representatives or agents makes any representation or warranty as to the accuracy, reasonableness or completeness of the information contained in this Presentation, and shall have no liability for any representations or warranties (expressed or implied) contained in, or for any omissions from or errors in, this Presentation or any other written or oral communications transmitted to the recipient in the course of its evaluation of the Company and this Presentation or any information in this Presentation to update, amend or supplement this Presentation or any information contained not to give undue weight to such industry and market data. Any and all trademarks and trade names referred to in this presentation are the property of their respective owners.

This Presentation contains financial forecasts with respect to the Company's projected financial results and operating data, as well as our long-term guidance. Neither the Company's independent auditors, nor its independent registered public accounting firm, has audited, reviewed, compiled or performed any procedures with respect to the projections for the purpose of their inclusion in this Presentation, and accordingly, neither of them expressed an opinion or provided any other form of assurance with respect thereto for the purpose of this Presentation. These projections should not be relied upon as being necessarily indicative of future results. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information, including those references under "forward-looking statements" above. Accordingly, there can be no assurance that the prospective results are indicative of the Company's future performance or that actual results will not differ materially from those presented in the prospective financial information. Inclusion of the prospective financial information in this Presentation should not be regarded as a representation by any person that the results contained in such prospective financial information will be achieved.

This Presentation and any oral statements made in connection with this Presentation shall not constitute an offer, nor a solicitation of an offer, of the sale or purchase of any securities, nor shall any securities of the Company be offered or sold, in any jurisdiction in which such an offer, solicitation or sale would be unlawful. Neither the SEC nor any state securities commission has approved or disapproved of the transactions contemplated hereby or determined if this Presentation is truthful or complete. Any representation to the contrary is a criminal offense. Nothing in this Presentation constitutes investment, tax or legal advice or a recommendation regarding any securities. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, must make your own decisions and perform your own independent investment and subjects, and, by accepting this Presentation, you confirm that you are not relying upon the information contained herein to make any decision.

INVESTMENT PORTFOLIO DISCLOSURE

All information provided for Solasglas Investments, LP is for informational purposes only and should not be deemed as investment advice or a recommendation to purchase or sell any specific security.

Performance returns reflect the total returns, net of fees and expenses. Returns are net of either the modified high water mark incentive allocation of 10% or the standard 20% incentive allocation.

All figures are unaudited. Greenlight Re and DME Advisors, LP ("DME") do not undertake to update any information contained herein as a result of audit adjustments or other corrections. Past performance is not indicative of future results. Actual returns may differ from the returns presented. Reference to an index does not imply that the fund will achieve returns, volatility or other results similar to the index. The total returns for the index do not reflect the deduction of any fees or expenses which would reduce returns.

All exposure information is calculated on a delta-adjusted basis and excludes "macro" positions, which may include, but are not limited to, government debt, currencies, commodities, credit default swaps, interest rate swaps, volatility indexes, credit indexes and derivatives on any of these instruments. However, equity indexes and derivatives on such instruments are included in long/short exposure. The largest disdosed long positions represent individual issuers to which the Solasglas has the highest exposure. All weightings, exposure, attribution and performance contribution information are the result of classifications and assumptions made in the sole judgment of DME.

The specific investments identified and described are not representative of all the positions held, purchased, or sold, and in the aggregate, the information may represent a small percentage of activity. It should not be assumed that any position identified has or will be profitable. There can be no guarantee that similar investment opportunities will be available in the future or that DME will be able to exploit similar investment opportunities should they arise. The information presented is intended to provide insight into the noteworthy events, in the sole opinion of the presenter, affecting the portfolio. The opinions expressed represent the current, good faith views of DME at the time of publication and are provided for limited purposes, are not definitive investment advice, and should not be relied on as such.

MANAGEMENT TEAM



Simon Burton Chief Executive Officer



Pat O'Brien Chief Executive Officer - Ireland



Neil Greenspan Chief Financial Officer



Faramarz Romer Chief Accounting Officer & Treasurer



Brian O'Reilly Head of Innovations



Laura Accurso General Counsel



Richard Strommer Chief Actuary



Tom Curnock Chief Risk Officer

Andy Gladwin

Active Underwriter – Syndicate 3456



Finbar Griffin Chief Underwriting Officer - Ireland



Kagabo Ngiruwonsanga* Head of Innovation Underwriting

GREENLIGHT





GREENLIGHT

GREENLIGHT CAPITAL RE, LTD.

GREENLIGHT RE

Entities & Licensing



¹ This rating represents the rating agency's opinion of our financial strength and ability to meet our ongoing insurance policy and contract obligations. It is not an evaluation directed toward the protection of investors or a recommendation to buy, sell, or hold our Class A ordinary shares.

A-

A-

Α

\$565 million Gross Written Premiums Year ended December 31st 2021

\$1.5 billion Total Assets At September 30, 2022

\$467 million Consolidated GAAP Capital At September 30, 2022

45 Employees As of November 11th 2022

29 Innovation Partners As of November 11th 2022



OUR OBJECTIVE

Maximize growth in Book Value Per Share within risk and operating constraints



THREE STRATEGIC PILLARS

Open Market Underwriting

Combination of lead and follow business determined by expertise and market intelligence

Small scale allows consistent review of all risks and dynamic allocation of capacity to best opportunities

Focus on short- and medium-tail risks where we can compete on similar terms with larger peers

Innovations

Leverage investment to provide optionality to participate in (re)insurance business

Early-stage investments

For each investment, we have a high level of:

- influence - diversification - option on future business

Solasglas Investments

Designed to achieve higher rates of return over the long term than more traditional investment strategies

Low correlation to underwriting

Long-short strategy reduces market exposure

Liquid portfolio

No material direct interest rate risk



UNDERWRITING PERFORMANCE VS. PEERS – COMBINED RATIOS

2020			
Arch	99.5%		
Scor	100.2%		
Greenlight Re	100.4%		
Hannover Re	101.6%		
Renaissance Re	101.9%		
Everest Re	103.0%		
Trans Re	103.6%		
Markel	103.7%		
Watford	103.7%		
AXIS	103.8%		
Munich Re	105.6%		
Partner Re	106.0%		
Argo	106.0%		
Lloyd's	110.3%		
Lancashire	107.8%		
Swiss Re	109.0%		
AXA XL	109.0%		
SiriusPoint	111.9%		

2021	
Partner Re	90.5%
Lloyd's	93.5%
Arch	94.2%
Swiss Re	97.1%
Hannover Re	97.7%
Everest Re	98.1%
AXIS	99.0%
Trans Re	99.4%
Munich Re	99.6%
Case	100.6%
Scor	100.6%
Scor Greenlight Re	100.8%
Greenlight Re	100.9%
Greenlight Re Renaissance Re	100.9% 102.1%
Greenlight Re Renaissance Re AXA XL	100.9% 102.1% 103.3%
Greenlight Re Renaissance Re AXA XL Markel	100.9% 102.1% 103.3% 105.3%
Greenlight Re Renaissance Re AXA XL Markel Argo	100.9% 102.1% 103.3% 105.3% 105.6%
Greenlight Re Renaissance Re AXA XL Markel Argo Lancashire	100.9% 102.1% 103.3% 105.3% 105.6% 107.3%
Greenlight Re Renaissance Re AXA XL Markel Argo Lancashire SiriusPoint	100.9% 102.1% 103.3% 105.3% 105.6% 107.3% 116.3%

YTD Q3 2022			
Partner Re	90.7%		
Markel	93.0%		
Munich Re	96.9%		
Argo	97.4%		
Arch	98.3%		
Axis	99.1%		
Hannover Re	99.2%		
Everest Re	99.8%		
Renaissance Re	103.6%		
Greenlight Re	104.8%		
Swiss Re	106.1%		
	106.1% 108.2%		
Swiss Re			
Swiss Re SiriusPoint	108.2%		
Swiss Re SiriusPoint Scor P&C	108.2% 119.5%		
Swiss Re SiriusPoint Scor P&C AXA XL Re	108.2% 119.5% N/a		
Swiss Re SiriusPoint Scor P&C AXA XL Re Conduit Re	108.2% 119.5% N/a N/a		
Swiss Re SiriusPoint Scor P&C AXA XL Re Conduit Re Convex	108.2% 119.5% N/a N/a N/a		
Swiss Re SiriusPoint Scor P&C AXA XL Re Conduit Re Convex Hamilton Re	108.2% 119.5% N/a N/a N/a N/a		

INNOVATIONS INVESTMENTS

Recorded significant and consistent unrealized investment gains over the last two years



¹See Note 4 of our condensed consolidated financial statements in our Form 10-Q for the nine months ended September 30, 2022, for a description of the accounting treatment applied to our Innovations investments.

GREENLIGHT

SOLASGLAS PERFORMANCE (net of fees)

2022 through October: **18.2%** 2021 full year: **7.5%**





GREENLIGHT

PRESERVATION OF CAPITAL

Change in GAAP Shareholders' Equity – YTD 2022



Source: public disclosures.

GREENLIGHT

PRICE-TO-BOOK



Share prices at November 11th, 2022, close and book values at Q3 2022 per public disclosures.

GREENLIGHT

UNDERWRITING OPPORTUNITY IS SIGNIFICANT

2022 reinsurance pricing conditions were the best we have seen in over a decade



Emergent pressures in 2022:

- Ukraine war
- Rapid increase in inflation
- Bond valuations
- Hurricane lan

2023 pricing conditions are likely to be better than 2022, perhaps significantly

Lloyd's Risk Adjusted Rate Change



LLOYD'S HAS RECORDED 19 CONSECUTIVE QUARTERS OF PRICE IMPROVEMENTS GREENLIGHT

INVESTMENT OUTLOOK

Innovations

Prospective opportunities:

- We believe early stage valuations are more attractive than in 2021
- Profitable MGAs are currently highly valued

Existing book:

- Our five largest partners (representing 77% of our carry value) have raised capital since October 2021 and we consider them well-funded
- Some partners are past the highest-risk phase of their execution

Solasglas Investments

Disciplined value-oriented strategy has been a significant contributor during the market turmoil of the last year

ENVIRONMENTAL, SOCIAL, & GOVERNANCE

We run our business as good corporate citizens & constructively engage with all of our stakeholders

Environmental

Across our underwriting book we intend to support a responsible "net zero" transition

Social

We support diversity, equality and inclusion

We publish statistics on our workforce by gender, sexual orientation and race

We support local charities and provide scholarships to foster youth education

Governance

In 2022, we revised executive compensation plans with increased focus on performance and shareholder alignment

During 2021 our Board was refreshed and diversity improved

GREENLIGHT



Underwriting and Innovations

PATRICK O'BRIEN Chief Executive Officer – Ireland

BRIAN O'REILLY Head of Innovations

OPEN MARKET REINSURANCE UNDERWRITING

We offer treaty reinsurance across a broad range of classes through our reinsurance entities in Cayman Islands and Ireland

Our focus is on underwriting reinsurance business profitably and in a disciplined manner

Our major operational priority is to take advantage of the market opportunities in the reinsurance sector following the completion of the repositioning of our portfolio

Open Market Reinsurance

Aviation and Space Marine and Energy Terror and Political Risk Mortgage Property Financial Lines Casualty (Auto, General Liability, Work Comp, D&O) Professional Lines Cyber

Funds at Lloyd's

Whole Account Quota Share of Lloyd's Syndicates

GREENLIGHT

OPEN MARKET REINSURANCE UNDERWRITING

	Inforce as at		
Class	6/1/2017	6/1/2021	7/1/2022
Personal Auto	48.2%	25.9%	0.5%
Property	6.0%	15.3%	27.3%
Workers' Compensation	10.9%	14.6%	7.3%
Casualty	8.8%	14.2%	25.0%
Specialty	1.0%	12.3%	22.0%
Financial Lines	8.2%	7.0%	15.8%
Health	11.4%	6.4%	1.3%
Multi-peril	5.6%	4.2%	0.7%

Bound programs					
Year	Cayman	Ireland	S3456	Total	Average premium (\$m)
2017	36	3		39	17.1
2018	39	11		50	14.3
2019	50	40		90	6.3
2020	48	50		98	4.5
2021	89	93		182	3.1
2022 YTD	111	99	8	218	2.4

- Portfolio is well-diversified by line of business and cedant
- Generally, we are a following market we benefit from the insights of recognized leaders
- Client list includes Lloyds and large global insurers
- Only 7% of current in-force premium was on the books in 2017

GREENLIGHT

OPEN MARKET REINSURANCE UNDERWRITING FUNDS AT LLOYD'S

- Lloyd's track record post-loss-event is favorable
- Lloyd's has demonstrated improvements in efficiency and profitability:
 - Non-cat loss ratio and expense ratio have reduced significantly
 - 19 quarters of rate increases
- FAL portfolio characteristics:
 - Relatively low natural cat risk
 - High level of risk diversification
 - High level of capital efficiency
- Generates additional reinsurance opportunities





OPEN MARKET REINSURANCE UNDERWRITING PROPERTY CAT

Hurricanes Harvey, Irma, and Maria struck in 2017, and cost us \$56m. We estimate our current exposure to a repeat of these events at \$24m.



Reduced our Cat appetite, with a material reduction in Florida exposure

Proforma is based on estimate of reoccurrence of HIM loss on in-force book as at September 30th 2022

INNOVATIONS OVERVIEW

We partner with and support early-stage Insurtechs

Currently, 29 minority investments

We are a market leader in early stage Insurtech space

We consider opportunities to monetize our market position



GREENLIGHT

GREENLIGHT RE

INNOVATIONS – STRATEGIC BENEFIT



SELECTED INNOVATIONS PARTNERS



GREENLIGHT

GREENLIGHT RE

INNOVATIONS UNDERWRITING

Our primary driver in making Insurtech investments is to support our (re)insurance business

Approach:

- We offer insurance capacity to our Innovations partners through Syndicate 3456 at Lloyd's
- We offer reinsurance capacity to our Innovations partners via fronting carriers, through our reinsurers in the Cayman Islands and Ireland
- Seeking opportunities that are accretive to our underwriting portfolio

Success To Date:

- We currently provide underwriting capacity to 15 of our Innovations partners
- Premium generated by Innovations opportunities represented 12% of Net Written Premium YTD September 30, 2022
- We expect this Innovations-related premium to grow significantly in 2023 and beyond



GREENLIGHT

RE

DAVID EINHORN Chairman of the Board

INVESTMENT APPROACH

- Greenlight Capital, an affiliate of DME Advisors, was founded in 1996
- DME Advisors analyzes available financial data, business strategies, and prospects to identify undervalued and overvalued securities
- Greenlight Re has implemented this value-oriented investment strategy since its formation
- Goal is to maximize total risk-adjusted return
- Average gross exposure of 88% long and 55% short between Aug 2004 Sep 2022

INVESTMENT PORTFOLIO

- Solasglas Investments, LP is the fund that holds all investment assets managed by DME Advisors
- DME Advisors is the general partner and owns approximately 26% of Solasglas
- Investment Portfolio is 50% of Greenlight Re's Adjusted Surplus
- Largest longs as of Oct 31, 2022: Brighthouse Financial, CONSOL Energy, Green Brick Partners, Kyndryl Holdings and Teck Resources
- 2022 performance (through Oct 31, 2022): +18.2% vs. S&P 500 index: -17.7%



⁽¹⁾ Through October 31, 2022. See "Investment Portfolio Disclosure" at the beginning of the presentation.

SOLASGLAS RISK MANAGEMENT

- Tighter investment guidelines and risk management post-2018
- Have reduced gross and net exposure in 2022
- Short portfolio changes:
 - Reduced single-name exposure due to meme stock phenomenon
 - Manage exposure through a combination of smaller position sizes and index/basket hedges
- Reduce sector risk by hedging with baskets of highly-correlated securities

GREFNI

GREENLIGHT RE

IS VALUE INVESTING DEAD?

BENJAMIN GRAHAM

AVESTOP

DENIAMIN ORAHAM



DME ADVISORS' CURRENT VIEW

- We are in a bear market that is likely to continue
- There is significant volatility in financial markets and a wider range of possible outcomes
- The Federal Reserve is in a bind
 - It has a systemic and embedded inflation problem
 - The economy has begun to slow
- Housing inflation will keep CPI elevated; wages are rising and sticky
- Ultimately, tightening will pose risks to financial stability and the Fed will be forced to ease before defeating inflation

SOLASGLAS PORTFOLIO POSITIONING

- On the long side:
 - The bar is high for new longs
 - Only one large position bought this year
 - Focused on high expected cash-on-cash returns
- On the short side:
 - Unprofitable companies
 - Event specific shorts
 - Specific hedges for large positions
- Manage exposures tightly and stockpile dry powder for upcoming opportunity set

GREENLIGHT

SOLASGLAS PORTFOLIO POSITIONING: MACRO

- Macro overlay to protect from exogenous shocks
- 2022 year-to-date attribution of returns

Gross Attribution		
Longs	-1.8%	
Shorts	20.4%	
Macro	3.1%	

- Credit spreads for tail risk
- Inflation swaps and interest rate derivatives
- Gold has been a detractor this year

GREENLIGHT

CAPITAL MANAGEMENT

- There are several competing uses for Greenlight Re's capital
 - Underwriting activities
 - Insurtech investments at our Innovations unit
 - Investment in Solasglas fund
 - Share buybacks
- There is tension between these uses of capital:
 - Share buybacks at the current discount to book value are the *best short-term use of capital*
 - But it reduces our equity and makes the business less competitive and more expensive to run

GREENLIGHT

CAPITAL MANAGEMENT

- Convertible notes
 - We issued \$100 million of convertible notes in August 2018
 - Repurchased \$20 million as of October 2022
 - Intend to refinance all or in part in an effort to preserve financial flexibility
- Solasglas fund
 - Greenlight Re expects to increase the allocation from 50% to 60% of Adjusted Surplus starting January 1

GREENLIGHT


GREENLIGHT

RE

NEIL GREENSPAN Chief Financial Officer

ASSETS AT SEPTEMBER 30, 2022 (unaudited) (Total assets: \$1.5 billion)



GREENLIGHT

LIABILITIES AT SEPTEMBER 30, 2022 (unaudited) (Total liabilities: \$1.1 billion)



GREENLIGHT

RESERVE STABILITY Prior-year development: Q1 2011 – Q3 2022 (2022 unaudited)



GREENLIGHT



RE

GREENLIGHT

Financial FAQs

FARAMARZ ROMER Chief Accounting Officer & Treasurer

Question 1: what is deposit interest expense?

FY 2016 – 2020: < \$1m in total FY 2021: \$12m YTD 2022 (unaudited): \$6m

We apply deposit accounting to reinsurance contracts that do not transfer sufficient insurance risk to merit reinsurance accounting

Heavily structured transactions: no longer a significant part of our underwriting strategy

Significant counterparty risk: no longer **any** part of our underwriting strategy

GREENLIGHT



Question 2: is restricted cash available for...

....investing in Solasglas?buying back stock or the convertible notes?generating investment return?

At September 30, 2022 (unaudited):

- Restricted cash and cash equivalents: \$649 million
- Total assets: \$1.5 billion

Restricted Cash

- Required to collateralize reinsurance obligations to cedants
- Amount dictated by contractual terms
- Provided via LOCs and Trusts



GREENLIGHT



Restricted Cash





Restricted Cash



* Unaudited

CONCLUSION

We believe that all components of our strategy poised to continue functioning well

Underwriting

- Market conditions are the best in more than a decade
- Reinsurance is cyclical and results lag; rate has decoupled from risk in some areas

Innovations

- We are a market leader in early-stage Insurtech sector
- Underwriting and investment market conditions are both compelling

Solasglas

Value-oriented strategy has been a significant contributor during recent market turmoil

GREENLIGHT



Question & Answer Session

DAVID EINHORN Chairman of the Board

SIMON BURTON Chief Executive Officer

PATRICK O'BRIEN Chief Executive Officer – Ireland

NEIL GREENSPAN Chief Financial Officer

FARAMARZ ROMER Chief Accounting Officer & Treasurer

BRIAN O'REILLY Head of Innovations



THANK YOU

